CSL Behering产品代理

Despite the constantly challenging environment the COVID-19 pandemic has presented to the world, CSL has remained steadfast in our promise to safeguarding our patients, our plasma donors and our employees. As the pandemic continues to evolve, so have we. CSL has redirected resources and taken

extra   commitments to protect public health where we could offer the most value,   including our expertise, technologies, equipment and materials. And through   it all, we continue to deliver on our promise for those who need us most, our   patients.

Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha 1 Antitrypsin Deficiency.